MedTrace Logo

Irritation and Sensitization Study of HP-5000 Topical System

NCT04882319 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-08-23

No results posted yet for this study

Summary

This study will assess skin irritation and sensitization for HP-5000 patch in healthy subjects.

Conditions

  • Osteoarthritis of the Knee

Interventions

DRUG

HP-5000 Topical Patch

HP-5000, placebo and saline will be administered simultaneously

DRUG

HP-5000 Placebo Patch

HP-5000, placebo and saline will be administered simultaneously

DRUG

Saline Patch

HP-5000, placebo and saline will be administered simultaneously

Sponsors & Collaborators

  • Noven Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Study Director · Noven Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-03
Primary Completion
2022-03-08
Completion
2022-03-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04882319 on ClinicalTrials.gov